Yoon Kyung Cho

Dr. Yoon Kyung Cho

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
5 December 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
BABin Ahn
Bin Ahn
KKKyuri Kang
Kyuri Kang
YKYe Ji Kim
Ye Ji Kim
YCYoon Kyung Cho
Yoon Kyung Cho
SJSuejung Jo
Suejung Jo
Hyun Mi KangHyun Mi Kang
Hyun Mi Kang
Background: Varicella can lead to severe complications in immunocompromised children, including those undergoing hematopoietic stem cell transplantation (HSCT) or chemotherapy. Preventing primary varicella zoster virus (VZV) infection is crucial in these populations to mitigate morbidity and mortality. This study aimed to evaluate the immunogenicity and safety of the live attenuated MAV/06 varicella vaccine in pediatric patients post-HSCT and post-chemotherapy. Additionally, it sought to compare fluorescent-antibody-to-membrane-antigen (FAMA) and enzyme-linked immunosorbent assay (ELISA) titers to establish effective cut-off levels for protection against varicella. Methods: The FAMA assay was conducted at the Vaccine Bio Research Institute, and a VARICELLA-ZOSTER ELISA (Vircell, Granada, Spain) kit, which relies on lysate from whole cells infected with VZV, was used to determine VZV IgG. A prospective cohort study was conducted with 76 pediatric patients under 18 years old who tested negative for VZV IgG via ELISA. Patients post-HSCT and post-chemotherapy were included. Participants received the MAV/06 varicella vaccine, and serologic responses were evaluated using ELISA and FAMA. Results: The median age of participants was 9.8 years, with acute lymphoid leukemia and acute myeloid leukemia being the most common underlying disease. Post-dose 1, the seropositive rate was 56.1% by ELISA and 97.2% by FAMA. Based on the FAMA seropositive cut-off ≥1:4, post-dose 1 geometric mean titers (GMTs) of seropositive patients in the post-HSCT group were 14.7 (95% CI, 11.3–19.1) versus 20.2 (95% CI, 13.0–31.3) in the post-chemotherapy group (p = 0.690). Based on a FAMA seropositive cut-off ≥1:16, the post-dose 1 GMT of patients considered seropositive in the post-HSCT group was 19.3 (95% CI, 15.6–24.0) versus 34.1 (95% CI, 21.0–55.4) in the post-chemotherapy group (p = 0.116), and post-dose 2 FAMA titers of 76.1 (95% CI, 14.6–398.1) in the post-HSCT group and 64.0 (95% CI, 11.4–358.1) in the post-HSCT group (p = 0.853) were observed. In patients with lower baseline FAMA titers (1:4 to 1:8), 66.7% in the post-HSCT group and 71.5% in the post-chemotherapy group achieved a greater than four-fold increase in FAMA titers post-dose 1, while those with higher baseline titers (≥1:16) did not. There were no serious adverse events or vaccine-related rashes occurring in any of the patients. Conclusion: The MAV/06 varicella vaccine is immunogenic in pediatric patients post-HSCT and post-chemotherapy, particularly when administered in a two-dose schedule using a cut-off FAMA titer of <1:16.

28 October 2024 in Vaccines
Verified
Journal Article
Open access
PDF file
MHMi yeon Hur
Mi yeon Hur
KKKyuri Kang
Kyuri Kang
YKYeJi Kim
YeJi Kim
YCYoon Kyung Cho
Yoon Kyung Cho
JLJae Wook Saint Lee
Jae Wook Saint Lee
Hyun Mi KangHyun Mi Kang
Hyun Mi Kang
Pediatric patients who have undergone hematopoietic stem cell transplantation (HSCT) or chemotherapy are at increased risk for severe influenza complications, necessitating annual vaccination. This study evaluated the immunogenicity and antibody persistence of the 2021–2022 seasonal quadrivalent influenza vaccine in pediatric patients post-HSCT or chemotherapy, compared to healthy controls. A prospective cohort study included 80 pediatric participants divided into three groups: chemotherapy (n = 33), HSCT (n = 27), and healthy controls (n = 20). All participants were vaccinated with the 2021–2022 GC FLU Quadrivalent vaccine. Hemagglutination inhibition (HI) assays measured seroprotection rates (SPR), geometric mean titers (GMT), and seroconversion rates (SCR) for the four vaccine antigens (A/H1N1, A/H3N2, B/Victoria, B/Yamagata) at one, three, and six months post-vaccination. At one month post-vaccination, all groups met the 70% SPR threshold for A/H1N1 and A/H3N2, but not for B/Victoria. For B/Yamagata, the SPR was low in the chemotherapy and HSCT groups (18.18% and 33.33%, respectively), compared to 80.00% in controls (p < 0.0001 and p = 0.0015). While A/H1N1 and A/H3N2 GMTs were protective in all groups, only controls achieved protective levels for B/Yamagata. Over time, the control group maintained >70% SPR for A/H1N1 up to six months, but the chemotherapy and HSCT groups declined by three and six months, respectively. For A/H3N2, the SPR in controls dropped below 70% at three months, while it remained above 70% in the chemotherapy and HSCT groups until three months. None of the groups achieved protective GMTs for B strains at three or six months. Pediatric patients post-HSCT or chemotherapy demonstrated a comparable immune response to healthy controls for A/H1N1 and A/H3N2, but the rapid decline in A/H1N1 antibody levels suggests the need for ongoing monitoring and adjusted vaccination schedules. The poor response to B antigens, particularly B/Yamagata, underscores the need for improved vaccination strategies in these vulnerable populations.

1 January 2025 in Infection & Chemotherapy
Verified
Journal Article
Open access
PDF file
YCYoon Kyung Cho
Yoon Kyung Cho
YKYe Ji Kim
Ye Ji Kim
SPShin Young Park
Shin Young Park
Hyun Mi KangHyun Mi Kang
Hyun Mi Kang
Cho YK, et al. Infect Chemother. 2025 Jun;57:e41. https://doi.org/10.3947/ic.2025.0049

1 January 2022 in Pediatric Infection & Vaccine
Verified
Journal Article
Open access
PDF file
YCYoon Kyung Cho
Yoon Kyung Cho
YLYeon Kyung Lee
Yeon Kyung Lee
SKSun Young Ko
Sun Young Ko
Cho YK, et al. Pediatr Infect Vaccine. 2022 Dec;29(3):161-165. https://doi.org/10.14776/piv.2022.29.e15

30 June 2026 in Kawasaki Disease
Verified
Journal Article
Open access
PDF file
YCYoon Kyung Cho
Yoon Kyung Cho
Soo-Young LeeSoo-Young Lee
Soo-Young Lee
Systemic juvenile idiopathic arthritis (SJIA) is an autoinflammatory disease characterized by fever, rash, and arthritis. In actual practice, SJIA is sometimes confused with Kawasaki disease (KD), as they share clinical and laboratory findings. Compared to those with KD, patients with SJIA present with more frequent joint symptoms and organ dysfunction and have more severe overall laboratory findings. However, it is important to note that clinical and laboratory findings of SJIA can also occur in severe forms of KD. Hyperferritinemia and elevated interleukin (IL)-18 levels are highly specific for SJIA and can serve as useful biomarkers for differentiating SJIA from KD. The most significant difference between SJIA and KD is the chronic nature of the disease course. Therefore, the possibility of overlooked SJIA should be considered in patients with KD who present with recurrent fever, rash, or arthritis. Approximately 0.5% of patients with KD are ultimately diagnosed with SJIA. Although the relationship between SJIA and KD is still partially understood, it will be an interesting and important research topic for KD-like hyperinflammatory diseases, including SJIA and KD.

5 February 2026 in Antibiotics
Verified
Journal Article
Open access
PDF file
HCHo Jung Choi
Ho Jung Choi
YCYoon Kyung Cho
Yoon Kyung Cho
YKYe Ji Kim
Ye Ji Kim
Hyun Mi KangHyun Mi Kang
Hyun Mi Kang
DJDae Chul Jeong
Dae Chul Jeong
IYIn Hyuk Yoo
In Hyuk Yoo
Background/Objectives: Azithromycin is widely recommended as the first-line treatment for pediatric Campylobacter enterocolitis, although supporting evidence is limited and there is a lack of studies evaluating the efficacy of other macrolide antibiotics. This study aims to assess the effectiveness of starting macrolide therapy within three days of symptom onset in pediatric patients with Campylobacter enterocolitis. Methods: Pediatric patients under 19 years of age with a new diagnosis of Campylobacter enterocolitis were enrolled and randomly assigned to receive macrolide antibiotic treatment with either azithromycin or clarithromycin in a 1:1 ratio. Additionally, a retrospective historical cohort of pediatric patients diagnosed with Campylobacter enterocolitis prior to the study period, who did not receive macrolide antibiotics, was retrospectively reviewed for comparison. This dual approach allowed for the evaluation of macrolide therapy’s effectiveness against untreated cases. Results: The study included 27 patients in the macrolide group and 37 patients in the non-macrolide group. Baseline demographic and clinical characteristics were comparable between groups. Early macrolide therapy was associated with reduced hospital stay (3.8 ± 0.7 vs. 4.5 ± 0.9 days), shorter duration of diarrhea (1.8 ± 1.2 vs. 3.4 ± 0.7 days, p < 0.001), and shorter duration of fever (1.1 ± 0.6 vs. 2.8 ± 1.0 days, p < 0.001). No significant difference was observed in the duration of vomiting (p = 0.061). Conclusions: Early initiation of macrolide antibiotics in children with Campylobacter enterocolitis significantly accelerated complete clinical resolution and shortened hospitalization, particularly by hastening the resolution of diarrhea, fever, and abdominal pain. These findings support the use of early macrolide therapy for pediatric Campylobacter enterocolitis.